

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

OSSEOR 2 g granules for oral suspension

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each sachet contains 2 g of strontium ranelate.

Excipient with known effect: Each sachet also contains 20 mg of aspartame (E951).

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Granules for oral suspension
Yellow granules

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Treatment of severe osteoporosis:

- in postmenopausal women,
- in adult men,

at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance. In postmenopausal women, strontium ranelate reduces the risk of vertebral and hip fractures (see section 5.1).

The decision to prescribe strontium ranelate should be based on an assessment of the individual patient's overall risks (see sections 4.3 and 4.4).

4.2 Posology and method of administration

Treatment should only be initiated by a physician with experience in the treatment of osteoporosis.

Posology

The recommended dose is one 2 g sachet once daily by oral administration.

Due to the nature of the treated disease, strontium ranelate is intended for long-term use.

The absorption of strontium ranelate is reduced by food, milk and derivative products and therefore, OSSEOR should be administered in-between meals. Given the slow absorption, OSSEOR should be taken at bedtime, preferably at least two hours after eating (see sections 4.5 and 5.2).

Patients treated with strontium ranelate should receive vitamin D and calcium supplements if dietary intake is inadequate.

Elderly patients

The efficacy and safety of strontium ranelate have been established in a broad age range (up to 100 years at inclusion) of postmenopausal women with osteoporosis. No dose adjustment is required in relation to age.

Patients with renal impairment

Strontium ranelate is not recommended for patients with severe renal impairment (creatinine clearance below 30 ml/min) (see sections 4.4 and 5.2). No dose adjustment is required in patients with mild-to-moderate renal impairment (30-70 ml/min creatinine clearance) (see section 5.2).

Patients with hepatic impairment

As strontium ranelate is not metabolised, no dose adjustment is required in patients with hepatic impairment.

Paediatric population

The safety and efficacy of OSSEOR in children aged below 18 years have not been established. No data are available.

Method of administration

For oral use.

The granules in the sachets must be taken as a suspension in a glass containing a minimum of 30 ml (approximately one third of a standard glass) of water.

Although in-use studies have demonstrated that strontium ranelate is stable in suspension for 24 hours after preparation, the suspension should be drunk immediately after being prepared.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Current or previous venous thromboembolic events (VTE), including deep vein thrombosis and pulmonary embolism.

Temporary or permanent immobilisation due to e.g. post-surgical recovery or prolonged bed rest.

Established, current or past history of ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.

Uncontrolled hypertension.

4.4 Special warnings and precautions for use

Cardiac ischaemic events

In pooled randomised placebo-controlled studies of post-menopausal osteoporotic patients, a significant increase in myocardial infarction has been observed in OSSEOR treated patients compared to placebo (see section 4.8).

Before starting treatment, patients should be evaluated with respect to cardiovascular risk.

Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with strontium ranelate after careful consideration (see sections 4.3 and 4.8).

During OSSEOR treatment, these cardiovascular risks should be monitored on a regular basis generally every 6 to 12 months.

Treatment should be stopped if the patient develops ischaemic heart disease, peripheral arterial disease, cerebrovascular disease or if hypertension is uncontrolled (see section 4.3).

Venous thromboembolism

In phase III placebo-controlled studies, strontium ranelate treatment was associated with an increase in the annual incidence of venous thromboembolism (VTE), including pulmonary embolism (see section 4.8). The cause of this finding is unknown. OSSEOR is contra-indicated in patients with a past

history of venous thromboembolic events (see section 4.3) and should be used with caution in patients at risk of VTE.

When treating patients over 80 years at risk of VTE, the need for continued treatment with OSSEOR should be re-evaluated.

OSSEOR should be discontinued as soon as possible in the event of an illness or a condition leading to immobilisation (see section 4.3) and adequate preventive measures taken. Therapy should not be restarted until the initiating condition has resolved and the patient is fully mobile. When a VTE occurs, OSSEOR should be stopped.

Use in patients with renal impairment

In the absence of bone safety data in patients with severe renal impairment treated with strontium ranelate, OSSEOR is not recommended in patients with a creatinine clearance below 30 ml/min (see section 5.2). In accordance with good medical practice, periodic assessment of renal function is recommended in patients with chronic renal impairment. Continuation of treatment with OSSEOR in patients developing severe renal impairment should be considered on an individual basis.

Skin reactions

Life-threatening cutaneous reactions (Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug rash with eosinophilia and systemic symptoms (DRESS)) have been reported with the use of OSSEOR.

Patients should be advised of the signs and symptoms and monitored closely for skin reactions. The highest risk for occurrence of SJS or TEN is within the first weeks of treatment and usually around 3-6 weeks for DRESS

If symptoms or signs of SJS or TEN (e.g. progressive skin rash often with blisters or mucosal lesions) or DRESS (e.g. rash, fever, eosinophilia and systemic involvement (e.g. adenopathy, hepatitis, interstitial nephropathy, interstitial lung disease) are present, OSSEOR treatment should be discontinued immediately.

The best results in managing SJS, TEN or DRESS come from early diagnosis and immediate discontinuation of any suspect drug. Early withdrawal is associated with a better prognosis. The outcome of DRESS is favorable in most cases upon discontinuation of OSSEOR and after initiation of corticosteroid therapy when necessary. Recovery could be slow and recurrences of the syndrome have been reported in some cases after discontinuation of corticosteroid therapy.

If the patient has developed SJS, TEN or DRESS with the use of OSSEOR, OSSEOR must not be restarted in this patient at any time.

A higher incidence, although still rare, of hypersensitivity reactions including skin rash, SJS or TEN in patients of Asian origin has been reported.

Interaction with laboratory test

Strontium interferes with colorimetric methods for the determination of blood and urinary calcium concentrations. Therefore, in medical practice, inductively coupled plasma atomic emission spectrometry or atomic absorption spectrometry methods should be used to ensure an accurate assessment of blood and urinary calcium concentrations.

Excipient

OSSEOR contains a source of phenylalanine, which may be harmful for people with phenylketonuria.

4.5 Interaction with other medicinal products and other forms of interaction

Food, milk and derivative products, and medicinal products containing calcium may reduce the bioavailability of strontium ranelate by approximately 60-70%. Therefore, administration of OSSEOR and such products should be separated by at least two hours (see section 5.2).

As divalent cations can form complexes with oral tetracycline and quinolone antibiotics at the gastrointestinal level and thereby reduce their absorption, simultaneous administration of strontium ranelate

with these medicinal products is not recommended. As a precautionary measure, OSSEOR treatment should be suspended during treatment with oral tetracycline or quinolone antibiotics.

An *in vivo* clinical interaction study showed that the administration of aluminium and magnesium hydroxides either two hours before or together with strontium ranelate caused a slight decrease in the absorption of strontium ranelate (20-25% AUC decrease), while absorption was almost unaffected when the antacid was given two hours after strontium ranelate. It is therefore preferable to take antacids at least two hours after OSSEOR. However, when this dosing regimen is impractical due to the recommended administration of OSSEOR at bedtime, concomitant intake remains acceptable.

No interaction was observed with oral supplementation of vitamin D.

No evidence of clinical interactions or relevant increase of blood strontium levels with medicinal products expected to be commonly prescribed concomitantly with OSSEOR in the target population were found during clinical trials. These included: nonsteroidal anti-inflammatory agents (including acetylsalicylic acid), anilides (such as paracetamol), H₂ blockers and proton pump inhibitors, diuretics, digoxin and cardiac glycosides, organic nitrates and other vasodilators for cardiac diseases, calcium channel blockers, beta blockers, ACE inhibitors, angiotensin II antagonists, selective beta-2 adrenoceptor agonists, oral anticoagulants, platelet aggregation inhibitors, statins, fibrates and benzodiazepine derivatives.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no data from the use of strontium ranelate in pregnant women.

At high doses, animal studies have shown reversible bone effects in the offspring of rats and rabbits treated during pregnancy (see section 5.3). If OSSEOR is used inadvertently during pregnancy, treatment must be stopped.

Breast-feeding

Physico-chemical data suggest excretion of Strontium ranelate in human milk OSSEOR should not be used during breast-feeding

Fertility

No effects were observed on males and females fertility in animal studies.

4.7 Effects on ability to drive and use machines

Strontium ranelate has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Summary of the safety profile

OSSEOR has been studied in clinical trials involving nearly 8,000 participants. Long-term safety has been evaluated in postmenopausal women with osteoporosis treated for up to 60 months with strontium ranelate 2 g/day (n=3,352) or placebo (n=3,317) in phase III studies. Mean age was 75 years at inclusion and 23% of the patients enrolled were 80 to 100 years of age.

There were no differences in the nature of adverse reactions between treatment groups regardless of whether patients were aged below or above 80 at inclusion.

Overall incidence rates for adverse reactions with strontium ranelate did not differ from placebo and adverse reactions were usually mild and transient. The most common adverse reactions consisted of nausea and diarrhoea, which were generally reported at the beginning of treatment with no noticeable

difference between groups afterwards. Discontinuation of therapy was mainly due to nausea (1.3% and 2.2% in the placebo and strontium ranelate groups respectively).

In phase III studies, the annual incidence of venous thromboembolism (VTE) observed over 5 years was approximately 0.7%, with a relative risk of 1.4 (95% CI = [1.0 ; 2.0]) in strontium ranelate treated patients as compared to placebo (see section 4.4).

In pooled randomised placebo-controlled studies of post-menopausal osteoporotic patients, a significant increase of myocardial infarction has been observed in OSSEOR treated patients as compared to placebo (1.7% versus 1.1 %), with a relative risk of 1.6 (95% CI = [1.07 ; 2.38]).

Tabulated list of adverse reactions

The following adverse reactions have been reported during clinical studies and/or post marketing use with Strontium ranelate. Adverse reactions, defined as adverse events considered at least possibly attributable to strontium ranelate treatment in phase III studies are listed below using the following convention (frequencies *versus* placebo): very common (>1/10); common (>1/100, <1/10); uncommon (>1/1,000, <1/100); rare (>1/10,000, <1/1,000); very rare (<1/10,000) ; not known (cannot be estimated from the available data).

| System Organ Class (SOC) <i>Frequency category</i> Adverse Reaction | Percentage of Patients Experiencing the adverse reaction | |
|---|--|------------------|
| | Treatment | |
| | Strontium ranelate (n=3352) | Placebo (n=3317) |
| Psychiatric disorders <i>Frequency unknown:^a</i> | | |
| Confusional state | - | - |
| Insomnia | - | - |
| Nervous system disorders <i>Common:</i> | | |
| Headache | 3.3% | 2.7% |
| Disturbances in consciousness | 2.6% | 2.1% |
| Memory loss | 2.5% | 2.0% |
| <i>Uncommon:</i> | | |
| Seizures | 0.4% | 0.1% |
| <i>Frequency unknown:^a</i> | | |
| Paraesthesia | - | - |
| Dizziness | - | - |
| Vertigo | - | - |
| Cardiac disorders <i>Common^d:</i> | | |
| Myocardial infarction | 1.7% | 1.1% |
| Vascular disorders <i>Common:</i> | | |
| Venous thromboembolism (VTE) | 2.7% | 1.9% |
| Respiratory, thoracic and mediastinal disorders <i>Frequency unknown:^a</i> | | |
| Bronchial hyperreactivity | - | - |
| Gastrointestinal disorders <i>Common:</i> | | |
| Nausea | 7.1% | 4.6% |
| Diarrhoea | 7.0% | 5.0% |
| Loose stools | 1.0% | 0.2% |

| | | |
|--|------|------|
| <i>Frequency unknown:</i> ^a | | |
| Vomiting | - | - |
| Abdominal pain | - | - |
| Oral mucosal irritation (stomatitis and/or mouth ulceration) | - | - |
| Gastrooesophageal reflux | - | - |
| Dyspepsia | - | - |
| Constipation | - | - |
| Flatulence | - | - |
| Dry mouth | - | - |
| Hepatobiliary disorders | | |
| <i>Frequency unknown:</i> ^a | | |
| Serum transaminase increased (in association with hypersensitivity skin reactions) | - | - |
| Hepatitis | - | - |
| Skin and subcutaneous tissue disorders | | |
| <i>Common:</i> | | |
| Dermatitis | 2.3% | 2.0% |
| Eczema | 1.8% | 1.4% |
| <i>Rare:</i> | | |
| DRESS (see section 4.4) | - | - |
| <i>Very rare:</i> | | |
| Severe cutaneous adverse reactions (SCARs): Stevens-Johnson syndrome and toxic epidermal necrolysis ^c (see section 4.4) | | |
| <i>Frequency unknown:</i> ^a | | |
| Hypersensitivity skin reactions (rash, pruritus, urticaria, angioedema) | - | - |
| Alopecia | - | - |
| Musculoskeletal and connective tissue disorders | | |
| <i>Frequency unknown:</i> ^a | | |
| Musculoskeletal pain (muscle spasm, myalgia, bone pain, arthralgia and pain in extremity) | - | - |
| General disorders and administration site conditions | | |
| <i>Frequency unknown:</i> ^a | | |
| Peripheral oedema | - | - |
| Pyrexia (in association with hypersensitivity skin reactions) | | |
| Malaise | | |
| Blood and Lymphatic disorders | | |
| <i>Frequency unknown:</i> ^a | | |
| Bone marrow failure | - | - |
| Eosinophilia (in association with hypersensitivity skin reactions) | - | - |
| Lymphadenopathy (in association with hypersensitivity skin reactions) | - | - |
| Investigations | | |
| <i>Common:</i> | | |
| Blood Creatine phosphokinase (CPK) increased ^b | 1.4% | 0.6% |

^a Post-marketing experience

^b Musculo-skeletal fraction > 3 times the upper limit of the normal range. In most cases, these values spontaneously reverted to normal without change in treatment.

^c In Asian countries reported as rare

^d In pooled placebo-controlled studies of post-menopausal osteoporotic patients, strontium ranelate treated patients (N=3803, 11270 patient years of treatment) compared to placebo (N=3769, 11250 patient years of treatment)

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via [the national reporting system listed in Appendix V](#).

4.9 Overdose

Symptoms

Good tolerance was shown in a clinical study investigating the repeated administration of 4 g strontium ranelate per day over 25 days in healthy postmenopausal women. Single administration of doses up to 11 g in healthy young male volunteers did not cause any particular symptoms.

Management

Following episodes of overdoses during clinical trials (up to 4 g/day for a maximal duration of 147 days), no clinically relevant events were observed.

Administration of milk or antacids may be helpful to reduce the absorption of the active substance. In the event of substantial overdose, vomiting may be considered to remove unabsorbed active substance.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Drugs for the treatment of bone diseases - Other drugs affecting bone structure and mineralisation, ATC code: M05BX03

Mechanism of action

In vitro, strontium ranelate:

- increases bone formation in bone tissue culture as well as osteoblast precursor replication and collagen synthesis in bone cell culture;
- reduces bone resorption by decreasing osteoclast differentiation and resorbing activity.

This results in a rebalance of bone turnover in favour of bone formation.

The activity of strontium ranelate was studied in various non-clinical models. In particular, in intact rats, strontium ranelate increases trabecular bone mass, trabeculae number and thickness; this results in an improvement of bone strength.

In bone tissue of treated animals and humans, strontium is mainly adsorbed onto the crystal surface and only slightly substitutes for calcium in the apatite crystal of newly formed bone. Strontium ranelate does not modify the bone crystal characteristics. In iliac crest bone biopsies obtained after up to 60 months of treatment with strontium ranelate 2 g/day in phase III trials, no deleterious effects on bone quality or mineralisation were observed.

The combined effects of strontium distribution in bone (see section 5.2) and increased X-ray absorption of strontium as compared to calcium, leads to an amplification of bone mineral density (BMD) measurement by dual-photon X-ray absorptiometry (DXA). Available data indicate that these factors account for approximately 50% of the measured change in BMD over 3 years of treatment with OSSEOR 2 g/day. This should be taken into account when interpreting BMD changes during treatment with OSSEOR. In phase III studies, which demonstrated the anti-fracture efficacy of OSSEOR treatment, measured mean BMD increased from baseline with OSSEOR by approximately 4% per year at the lumbar spine and 2% per year at the femoral neck, reaching 13% to 15% and 5% to 6% respectively after 3 years, depending on the study.

In phase III studies, as compared to placebo, biochemical markers of bone formation (bone-specific alkaline phosphatase and C-terminal propeptide of type I procollagen) increased and those of bone resorption (serum C-telopeptide and urinary N-telopeptide cross links) decreased from the third month of treatment up to 3 years.

Secondary to the pharmacological effects of strontium ranelate, slight decreases in calcium and parathyroid hormone (PTH) serum concentrations, increases in blood phosphorus concentrations and in total alkaline phosphatase activity were observed, with no observed clinical consequences.

Clinical efficacy

Osteoporosis is defined as BMD of the spine or hip 2.5 SD or more below the mean value of a normal young population. A number of risk factors are associated with postmenopausal osteoporosis including low bone mass, low bone mineral density, early menopause, a history of smoking and a family history of osteoporosis. The clinical consequence of osteoporosis is fractures. The risk of fractures is increased with the number of risk factors.

Treatment of postmenopausal osteoporosis:

The anti-fracture studies program of OSSEOR was made up of two placebo-controlled phase III studies: SOTI study and TROPOS study. SOTI involved 1,649 postmenopausal women with established osteoporosis (low lumbar BMD and prevalent vertebral fracture) and a mean age of 70 years. TROPOS involved 5,091 postmenopausal women with osteoporosis (low femoral neck BMD and prevalent fracture in more than half of them) and a mean age of 77 years. Together, SOTI and TROPOS enrolled 1,556 patients over 80 years at inclusion (23.1% of the study population). In addition to their treatment (2 g/day strontium ranelate or placebo), the patients received adapted calcium and vitamin D supplements throughout both studies.

OSSEOR reduced the relative risk of new vertebral fracture by 41% over 3 years in the SOTI study (table 1). The effect was significant from the first year. Similar benefits were demonstrated in women with multiple fractures at baseline. With respect to clinical vertebral fractures (defined as fractures associated with back pain and/or a body height loss of at least 1 cm), the relative risk was reduced by 38%. OSSEOR also decreased the number of patients with a body height loss of at least 1 cm as compared to placebo. Quality of life assessment on the QUALIOST specific scale as well as the General Health perception score of the SF-36 general scale indicated benefit of OSSEOR, compared with placebo.

Efficacy of OSSEOR to reduce the risk of new vertebral fracture was confirmed in the TROPOS study, including for osteoporotic patients without fragility fracture at baseline.

Table 1: Incidence of patients with vertebral fracture and relative risk reduction

| | Placebo | OSSEOR | Relative Risk Reduction vs. placebo (95%CI), p value |
|--|---------|--------|--|
| SOTI | N=723 | N=719 | |
| New vertebral fracture over 3 years | 32.8% | 20.9% | 41% (27-52), p<0.001 |
| New vertebral fracture over the 1 st year | 11.8% | 6.1% | 49% (26-64), p<0.001 |
| New clinical vertebral fracture over 3 years | 17.4% | 11.3% | 38% (17-53), p<0.001 |
| TROPOS | N=1823 | N=1817 | |
| New vertebral fracture over 3 years | 20.0% | 12.5% | 39% (27-49), p<0.001 |

In patients over 80 years of age at inclusion, a pooled analysis of SOTI and TROPOS studies showed that OSSEOR reduced the relative risk of experiencing new vertebral fractures by 32% over 3 years (incidence of 19.1% with strontium ranelate vs. 26.5% with placebo).

In an *a-posteriori* analysis of patients from the pooled SOTI and TROPOS studies with baseline lumbar spine and / or femoral neck BMD in the osteopenic range and without prevalent fracture but with at least one additional risk factor for fracture (N=176), OSSEOR reduced the risk of a first vertebral fracture by 72% over 3 years (incidence of vertebral fracture 3.6% with strontium ranelate vs. 12.0% with placebo).

An *a-posteriori* analysis was performed on a subgroup of patients from the TROPOS study of particular medical interest and at high-risk of fracture [defined by a femoral neck BMD T-score ≤ -3 SD (manufacturer's range corresponding to -2.4 SD using NHANES III) and an age ≥ 74 years (n=1,977, i.e. 40% of the TROPOS study population)]. In this group, over 3 years of treatment, OSSEOR reduced the risk of hip fracture by 36% relative to the placebo group (table 2).

Table 2: Incidence of patients with hip fracture and relative risk reduction in patients with BMD ≤ -2.4 SD (NHANES III) and age ≥ 74 years

| | Placebo | OSSEOR | Relative Risk Reduction vs. placebo (95%CI), p value |
|---------------------------|---------|--------|--|
| TROPOS | N=995 | N=982 | |
| Hip fracture over 3 years | 6.4% | 4.3% | 36% (0-59), p=0.046 |

Treatment of Osteoporosis in men:

The efficacy of OSSEOR was demonstrated in men with osteoporosis in a 2-year, double-blind, placebo-controlled study with a main analysis after one year in 243 patients (Intention to treat population, 161 patients received strontium ranelate) at high risk of fracture (mean age 72,7 years; mean lumbar BMD T-score value of -2.6; 28% of prevalent vertebral fracture).

All patients received daily supplemental calcium (1000 mg) and vitamin D (800 UI).

Statistically significant increases in BMD were observed as early as 6 months following initiation of OSSEOR treatment versus placebo.

Over 12 months, a statistically significant increase in mean lumbar spine BMD, main efficacy criteria (E (SE) = 5.32% (0.75); 95% CI = [3.86 ; 6.79]; p<0,001), similar to that observed in the pivotal anti-fracture phase III studies carried-out in postmenopausal women, was observed.

Statistically significant increases in femoral neck BMD and total hip BMD (p<0,001) were observed after 12 months.

Paediatric population

The European Medicines Agency has waived the obligation to submit the results of studies with OSSEOR in all subsets of the paediatric population in osteoporosis (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

Strontium ranelate is made up of 2 atoms of stable strontium and 1 molecule of ranelic acid, the organic part permitting the best compromise in terms of molecular weight, pharmacokinetics and acceptability of the medicinal product. The pharmacokinetics of strontium and ranelic acid have been assessed in healthy young men and healthy postmenopausal women, as well as during long-term exposure in men with osteoporosis and postmenopausal osteoporotic women including elderly women.

Due to its high polarity, the absorption, distribution and binding to plasma proteins of ranelic acid are low. There is no accumulation of ranelic acid and no evidence of metabolism in animals and humans. Absorbed ranelic acid is rapidly eliminated unchanged via the kidneys.

Absorption

The absolute bioavailability of strontium is about 25% (range 19-27%) after an oral dose of 2 g strontium ranelate. Maximum plasma concentrations are reached 3-5 hours after a single dose of 2 g. Steady state is reached after 2 weeks of treatment. Intake of strontium ranelate with calcium or food reduces the bioavailability of strontium by approximately 60-70%, compared with administration 3 hours after a meal. Due to the relatively slow absorption of strontium, food and calcium intake should be avoided both before and after administration of OSSEOR. Oral supplementation with vitamin D has no effect on strontium exposure.

Distribution

Strontium has a volume of distribution of about 1 l/kg. The binding of strontium to human plasma proteins is low (25%) and strontium has a high affinity for bone tissue. Measurement of strontium concentration in iliac crest bone biopsies from patients treated for up to 60 months with strontium ranelate 2 g/day indicate that bone strontium concentrations may reach a plateau after about 3 years of treatment. There are no data in patients to demonstrate elimination kinetics of strontium from bone off-therapy.

Biotransformation

As a divalent cation, strontium is not metabolised. Strontium ranelate does not inhibit cytochrome P450 enzymes.

Elimination

The elimination of strontium is time and dose independent. The effective half-life of strontium is about 60 hours. Strontium excretion occurs via the kidneys and the gastrointestinal tract. Its plasma clearance is about 12 ml/min (CV 22%) and its renal clearance about 7 ml/min (CV 28%).

Pharmacokinetics in special clinical situations

Elderly

Population pharmacokinetic data showed no relationship between age and apparent clearance of strontium in the target population.

Renal impairment

In patients with mild-to-moderate renal impairment (30-70 ml/min creatinine clearance), strontium clearance decreases as creatinine clearance decreases (approximately 30% decrease over the creatinine clearance range 30 to 70 ml/min) and thereby induces an increase in strontium plasma levels. In phase III studies, 85% of the patients had a creatinine clearance between 30 and 70 ml/min and 6% below 30 ml/min at inclusion, and the mean creatinine clearance was about 50 ml/min. No dosage adjustment is therefore required in patients with mild-to-moderate renal impairment. There is no pharmacokinetic data in patients with severe renal impairment (creatinine clearance below 30 ml/min).

Hepatic impairment

There is no pharmacokinetic data in patients with hepatic impairment. Due to the pharmacokinetic properties of strontium, no effect is expected.

5.3 Preclinical safety data

Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenic potential.

Chronic oral administration of strontium ranelate at high doses in rodents induced bone and tooth abnormalities, mainly consisting of spontaneous fractures and delayed mineralisation that were reversible after cessation of treatment. These effects were reported at bone strontium levels 2-3 times higher than bone strontium levels in humans up to 3 years of treatment. The data on skeletal strontium ranelate accumulation in longer term exposure is limited.

Developmental toxicity studies in rats and rabbits resulted in bone and tooth abnormalities (e.g. bent long bones and wavy ribs) in the offspring. In rats, these effects were reversible 8 weeks after cessation of treatment.

Environmental Risk Assessment (ERA)

The environmental risk assessment of strontium ranelate has been conducted in accordance to European guidelines on ERA.

Strontium ranelate does not present a risk for the environment.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Aspartame (E951)

Maltodextrin

Mannitol (E421)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

- 3 years.
- Once reconstituted in water, the suspension is stable for 24 hours. However, it is recommended to drink the suspension immediately after preparation (see section 4.2)

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

Paper/polyethylene/aluminium/polyethylene sachets.

Pack sizes

Boxes containing 7, 14, 28, 56, 84 or 100 sachets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements.

7. MARKETING AUTHORISATION HOLDER

LES LABORATOIRES SERVIER

50, rue Carnot

92284 Suresnes cedex
France

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/04/287/001
EU/1/04/287/002
EU/1/04/287/003
EU/1/04/287/004
EU/1/04/287/005
EU/1/04/287/006

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 21/09/2004
Date of latest renewal: 21/09/2009

10. DATE OF REVISION OF THE TEXT

MM/YYYY

Detailed information on this medicinal product is available on the website of the European Medicines Agency: <http://www.ema.europa.eu>

ANNEX II

- A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**
- D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release

Les Laboratoires Servier Industrie
905, route de Saran
45520 Gidy
France

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

• Periodic Safety Update Reports

The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

• Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.

• Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

| Description |
|---|
| Non-interventional safety study to evaluate the effectiveness of the applied risk minimisation measures, including a description of the treated patient population in everyday clinical practice, patterns of use and cardiovascular risk. After approval of the protocol, annual reports from this study shall be provided within the PSUR until submission of the final study report, which is due by December 2017. |

Additional risk minimisation measures

In each Member State where OSSEOR is marketed, the Marketing Authorisation Holder (MAH) shall agree the final educational programme with the National Competent Authority.

The MAH shall ensure that, following discussion and agreement with the National Competent Authority in each Member State where OSSEOR is marketed, all physicians who are expected to prescribe OSSEOR are provided with the following educational package:

- SmPC
- Package leaflet
- Prescriber guide and checklist
- Patient alert card

The prescriber guide and checklist shall contain the following key messages:

- OSSEOR is only indicated for use in patients with severe osteoporosis at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance.
- The initiation of treatment with OSSEOR should be based on an assessment of the individual patient's overall risk.
- All patients should be fully informed that cardiovascular risks should be monitored on a regular basis generally every 6-12 months.
- The patient alert card should be given to every patient.
- OSSEOR is contraindicated and must not be used in patients with :
 - Established, current or past history of ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.
 - Uncontrolled hypertension.
 - Current or previous venous thromboembolic events (VTE), including deep vein thrombosis and pulmonary embolism.
 - Temporary or permanent immobilisation due to e.g. post-surgical recovery or prolonged bed rest.
 - Hypersensitivity to the active substance (strontium ranelate) or any of the excipients.
- OSSEOR should only be used with caution in:
 - Patients with significant risk factors for cardiovascular events such as hypertension, hyperlipidaemia, diabetes mellitus or smoking.
 - Patients at risk of VTE. When treating patients over 80 years at risk of VTE, the need for continued treatment with OSSEOR should be re-evaluated.
- The treatment should be either discontinued or stopped in the following situations:
 - If the patient develops ischaemic heart disease, peripheral arterial disease, cerebrovascular disease or if hypertension is uncontrolled, the treatment should be stopped.
 - As soon as possible in the event of an illness or a condition leading to immobilization, the treatment should be discontinued.
 - If symptoms or signs of Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN) or Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) (e.g. rash, fever, eosinophilia and systemic involvement, e.g. adenopathy, hepatitis, interstitial nephropathy, interstitial lung disease) are present, OSSEOR treatment should be discontinued immediately. If the patient

has developed SJS, TEN or DRESS with the use of OSSEOR, OSSEOR must not be re-started.

- Within the prescriber guide there will be a check-list to remind prescribers of the contraindications, warnings and precautions prior to prescribing and to support the regular monitoring of cardiovascular risk.

The patient alert card shall contain the following key messages:

- Importance of showing the patient alert card to any Health Care Professional involved in their treatment.
- The contraindications to the treatment with OSSEOR.
- Key signs and symptoms of myocardial infarction, VTE and serious skin reactions.
- When to seek urgent medical advice.
- Importance of regularly monitoring cardiovascular risk.

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

Outer carton

1. NAME OF THE MEDICINAL PRODUCT

OSSEOR 2 g granules for oral suspension
Strontium ranelate

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each sachet contains 2 g strontium ranelate.

3. LIST OF EXCIPIENTS

Also contains aspartame (E 951).

4. PHARMACEUTICAL FORM AND CONTENTS

Granules for oral suspension.
7 sachets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral use
Read the package leaflet before use



| | Week |
|-----------|--------------------------|
| Monday | <input type="checkbox"/> |
| Tuesday | <input type="checkbox"/> |
| Wednesday | <input type="checkbox"/> |
| Thursday | <input type="checkbox"/> |
| Friday | <input type="checkbox"/> |
| Saturday | <input type="checkbox"/> |
| Sunday | <input type="checkbox"/> |

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Les Laboratoires Servier
50, rue Carnot
92284 Suresnes cedex
France

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/04/287/001

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

OSSEOR 2 g

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

Outer carton

1. NAME OF THE MEDICINAL PRODUCT

OSSEOR 2 g granules for oral suspension
Strontium ranelate

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each sachet contains 2 g strontium ranelate.

3. LIST OF EXCIPIENTS

Also contains aspartame (E 951).

4. PHARMACEUTICAL FORM AND CONTENTS

Granules for oral suspension.
14 sachets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral use
Read the package leaflet before use



| | Week | |
|-----------|--------------------------|--------------------------|
| | 1 | 2 |
| Monday | <input type="checkbox"/> | <input type="checkbox"/> |
| Tuesday | <input type="checkbox"/> | <input type="checkbox"/> |
| Wednesday | <input type="checkbox"/> | <input type="checkbox"/> |
| Thursday | <input type="checkbox"/> | <input type="checkbox"/> |
| Friday | <input type="checkbox"/> | <input type="checkbox"/> |
| Saturday | <input type="checkbox"/> | <input type="checkbox"/> |
| Sunday | <input type="checkbox"/> | <input type="checkbox"/> |

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Les Laboratoires Servier
50, rue Carnot
92284 Suresnes cedex
France

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/04/287/002

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

OSSEOR 2 g

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

Outer carton

1. NAME OF THE MEDICINAL PRODUCT

OSSEOR 2 g granules for oral suspension
Strontium ranelate

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each sachet contains 2 g strontium ranelate.

3. LIST OF EXCIPIENTS

Also contains aspartame (E 951).

4. PHARMACEUTICAL FORM AND CONTENTS

Granules for oral suspension.
28 sachets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral use
Read the package leaflet before use



| | Week | Week | Week | Week |
|-----------|--------------------------|--------------------------|--------------------------|--------------------------|
| | 1 | 2 | 3 | 4 |
| Monday | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Tuesday | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Wednesday | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Thursday | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Friday | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Saturday | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Sunday | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Les Laboratoires Servier
50, rue Carnot
92284 Suresnes cedex
France

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/04/287/003

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

OSSEOR 2 g

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

Outer carton

1. NAME OF THE MEDICINAL PRODUCT

OSSEOR 2 g granules for oral suspension
Strontium ranelate

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each sachet contains 2 g strontium ranelate.

3. LIST OF EXCIPIENTS

Also contains aspartame (E 951).

4. PHARMACEUTICAL FORM AND CONTENTS

Granules for oral suspension.
56 sachets
84 sachets
100 sachets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral use
Read the package leaflet before use



6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Les Laboratoires Servier
50, rue Carnot
92284 Suresnes cedex
France

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/04/287/004 56 sachets
EU/1/04/287/005/ 84 sachets (3 packs of 28)
EU/1/04/287/006 100 sachets

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

OSSEOR 2 g

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Sachet

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

OSSEOR 2 g granules for oral suspension.
Strontium ranelate.
For oral use.

2. METHOD OF ADMINISTRATION



3. EXPIRY DATE

EXP

4. BATCH NUMBER

Batch

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

2 g

6. OTHER

Read the package leaflet before use

B. PACKAGE LEAFLET

Package leaflet: Information for the patient

OSSEOR 2 g granules for oral suspension Strontium ranelate

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or your pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet:

1. What OSSEOR is and what it is used for
2. What you need to know before you take OSSEOR
3. How to take OSSEOR
4. Possible side effects
5. How to store OSSEOR
6. Contents of the pack and other information

1. What osseor is and what it is used for

OSSEOR is a non-hormonal medicine used to treat severe osteoporosis:

- in postmenopausal women,
- in men,

at high risk of fracture, for whom other alternative treatments are not possible. In postmenopausal women, strontium ranelate reduces the risk of fracture at the spine and at the hip.

About osteoporosis

Your body is constantly breaking down old bone and making new bone tissue. If you have osteoporosis, your body breaks down more bone than it forms so that gradually bone loss occurs and your bones become thinner and fragile. This is especially common in women after the menopause. Many people with osteoporosis have no symptoms and you may not even know that you have it. However, osteoporosis makes you more likely to have fractures (break bones), especially in your spine, hips and wrists.

How OSSEOR works

OSSEOR, which contains the substance strontium ranelate, belongs to a group of medicines used to treat bone diseases.

OSSEOR works by reducing bone breakdown and stimulating rebuilding of bone and therefore reduces the risk of fracture. The newly formed bone is of normal quality.

2. What you need to know before you take osseor

Do not take OSSEOR:

- if you are allergic to strontium ranelate or any of the other ingredients of OSSEOR (listed in section 6).

- if you have or have had a blood clot (for example, in the blood vessels in your legs or lungs).
- if you are immobilised permanently or for some time such as being wheel-chair bound, or confined to bed or if you are to undergo an operation or recovering from an operation. The risk of vein thrombosis (blood clots in the leg or lungs) may be increased in the event of lengthy immobilisation.
- if you have established ischaemic heart disease, or cerebrovascular disease, e.g. you have been diagnosed with a heart attack, stroke, or transient ischaemic attack (temporary reduction of blood flow to the brain; also known as “mini-stroke”), angina, or blockages of blood vessels to the heart or brain.
- if you have or have had problems with your blood circulation (peripheral arterial disease) or if you have had surgery on the arteries of your legs.
- if you have high blood pressure not controlled by treatment.

Warnings and precautions:

Talk to your doctor or pharmacist before taking OSSEOR:

- if you are at risk of heart disease, this includes high blood pressure, high cholesterol, diabetes, smoking.
- if you are at risk of blood clots.
- if you have severe kidney disease

Your doctor will evaluate the conditions of your heart and blood vessels regularly, generally every 6 to 12 months for as long you are taking OSSEOR.

During treatment, if you experience an allergic reaction (such as swelling of the face, tongue or throat, difficulty in breathing or swallowing, skin rash), you must immediately stop taking OSSEOR and seek medical advice.

Potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis and severe hypersensitivity reactions (DRESS)) have been reported with the use of OSSEOR.

Stevens-Johnson syndrome and toxic epidermal necrolysis appear initially as reddish target-like spots or circular patches often with central blisters on the trunk. Additional signs to look for include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). These potentially life-threatening skin rashes are often accompanied by flu-like symptoms. The rash may progress to widespread blistering or peeling of the skin.

DRESS appears initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes.

The highest risk of occurrence of serious skin reactions is within the first weeks of treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis and usually around 3-6 weeks for DRESS.

If you have developed Stevens-Johnson syndrome or toxic epidermal necrolysis or DRESS with the use of OSSEOR, you must not be re-started on OSSEOR at any time

If you develop a rash or these skin symptoms, stop taking OSSEOR, seek urgent advice from a doctor and tell him that you are taking this medicine.

If you are of Asian origin, talk to your doctor before taking OSSEOR as you may be at higher risk of skin reactions.

Children and adolescents

OSSEOR is not intended for use in children and adolescents (below the age of 18).

Other medicines and OSSEOR:

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

-You should stop taking OSSEOR if you have to take oral tetracyclines or quinolones (two types of antibiotics). You can take OSSEOR again when you have finished taking these antibiotics. If you are unsure about this ask your doctor or pharmacist.

- If you are taking medicines containing calcium, you should leave at least 2 hours before you take OSSEOR.
- If you take antacids (medicines to relieve heartburn) you should take them at least 2 hours after OSSEOR. If this is not possible, it is acceptable to take the two medicines at the same time.

OSSEOR with food and drink:

Food, milk and milk products reduce the absorption of strontium ranelate. It is recommended that you take OSSEOR in-between meals, preferably at bedtime at least two hours after food, milk or milk products or calcium supplements.

Pregnancy and breast-feeding:

Do not take OSSEOR during pregnancy or when you are breastfeeding. If you take it by accident during pregnancy or breastfeeding, stop taking it straight away and talk to your doctor.

Driving and using machines:

Osseor is unlikely to affect your ability to drive or use machines.

OSSEOR contains aspartame:

If you suffer from phenylketonuria (a rare, hereditary disorder of the metabolism) talk to your doctor before you start to take this medicine.

3. How to take osseor

The treatment should only be started by a doctor with experience of treating osteoporosis.

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

OSSEOR is for oral use.

The recommended dose is one 2g sachet a day.

It is recommended that you take OSSEOR at bedtime, preferably at least 2 hours after dinner. You may lie down immediately after taking OSSEOR if you wish.

Take the granules contained in the sachets as a suspension in a glass of water (see instructions below). OSSEOR can interact with milk and milk products, so it is important that you mix OSSEOR only with water to be sure it works properly.



Empty the granules from the sachet into a glass;



Add water;



Stir until the granules are evenly dispersed in the water.

Drink straight away. You should not leave it more than 24 hours before you drink it. If for some reason you cannot drink the medicine straight away, make sure you stir it again before drinking.

Your doctor may advise you to take calcium and vitamin D supplements in addition to OSSEOR. Do not take calcium supplements at bedtime, at the same time as OSSEOR.

Your doctor will tell you how long you should continue to take OSSEOR. Osteoporosis-therapy is usually required for a long period. It is important that you continue taking OSSEOR for as long as your doctor prescribes the medicine.

If you take more OSSEOR than you should:

If you take too many sachets of OSSEOR, tell your doctor or pharmacist. They may advise you to drink milk or take antacids to reduce the absorption of the active ingredient.

If you forget to take OSSEOR:

Do not take a double dose to make up for forgotten individual doses. Just carry on with the next dose at the normal time.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The frequency of possible side effects listed below is defined using the following convention:

very common: may affect more than 1 in 10 people

common: may affect 1 in 10 people

uncommon: may affect 1 in 100 people

rare: may affect up to 1 in 1,000 people

very rare: may affect up to 1 in 10,000 people

not known: frequency cannot be estimated from the available data

Common:

Heart attack may occur commonly in patients at high risk for heart disease. Your doctor will not prescribe OSSEOR for you if you are at particular risk.

Blood clots. Signs of a blood clot include painful swelling in your leg, sudden chest pain or difficulty breathing. See a doctor straight away if you experience any of these symptoms.

Nausea, diarrhoea, headache, skin irritation, memory troubles, fainting fit. However, these effects were mild and short-lived and usually did not cause the patients to stop taking their treatment. Talk to your doctor if any effects become troublesome or persist.

Uncommon:

Seizures.

Rare:

Severe hypersensitivity reactions (DRESS: see section 2)

Very rare:

Potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported (see section 2).

Not known:

Vomiting, abdominal pain, reflux, indigestion, constipation, flatulence, dry mouth, pins and needles, dizziness, vertigo, difficulty in sleeping, inflammation of the liver (hepatitis), oral irritation (such as mouth ulcers and gum inflammation), bone, muscle and/or joint pain, muscle cramps, hair loss, reduction in production of blood cells in the bone marrow, itching, hives, blistering, angioedema

(such as swollen face, tongue or throat, difficulty in breathing or swallowing), swelling in limbs, feeling unwell, feeling confused, bronchial hyperreactivity (symptoms include wheezing, shortness of breath and cough).

If you have stopped treatment due to hypersensitivity reactions, do not take OSSEOR again

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via **the national reporting system** listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store OSSEOR

Keep this medicine out of the sight and reach of children.

This medicinal product does not require any special storage conditions.

Do not use this medicine after the expiry date which is stated on the box and the sachet after EXP. The expiry date refers to the last day of that month.

Once reconstituted in water, the suspension is stable for 24 hours. However, it is recommended to drink the suspension immediately after preparation (see section 3)

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What OSSEOR contains

- The active substance is strontium ranelate. Each sachet contains 2 g of strontium ranelate.
- The other ingredients are aspartame (E 951), maltodextrin, mannitol (E 421).

What OSSEOR looks like and contents of the pack

OSSEOR is available in sachets containing yellow granules for oral suspension. OSSEOR is supplied in boxes of 7, 14, 28, 56, 84 or 100 sachets.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder

Les Laboratoires Servier
50, rue Carnot
92284 Suresnes cedex
France

Manufacturer

Les Laboratoires Servier Industrie
905, route de Saran
45520 Gidy
France

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.

België/Belgique/Belgien

S.A. Servier Benelux N.V.
Tel: +32 (0)2 529 43 11

България

Сервие Медикал ЕООД
Тел.: +359 2 921 57 00

Česká republika

Servier s.r.o.
Tel: +420 222 118 111

Danmark

Servier Danmark A/S
Tlf: +45 36 44 22 60

Deutschland

Servier Deutschland GmbH
Tel: +49 (0)89 57095 01

Eesti

CentralPharma Communications OÜ
Tel: +372 640 00 07

Ελλάδα

ΣΕΡΒΙΕ ΕΛΛΑΣ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΠΕ
Τηλ: +30 210 939 1000

España

Laboratorios Farmacéuticos Rovi, S.A.
Tel: +34 91 375 62 30

France

Les Laboratoires Servier
Tel: +33 (0)1 55 72 60 00

Hrvatska

Servier Pharma, d. o. o.
Tel.: +385 (0)1 3016 222

Ireland

Servier Laboratories (Ireland) Ltd.
Tel: +353 (0)1 6638110

Ísland

Servier Laboratories
c/o Icepharma hf
Sími: +354 540 8000

Italia

I.F.B. Stroder S.r.l.

Lietuva

UAB "SERVIER PHARMA"
Tel: +370 (5) 2 63 86 28

Luxembourg/Luxemburg

S.A. Servier Benelux N.V.
Tel: +32 (0)2 529 43 11

Magyarország

Servier Hungaria Kft.
Tel: +36 1 238 7799

Malta

Galepharma Ltd
Tel: +(356) 21 247 082

Nederland

Servier Nederland Farma B.V.
Tel: +31 (0)71 5246700

Norge

Servier Danmark A/S
Tlf: +45 36 44 22 60

Österreich

Servier Austria GmbH
Tel: +43 (1) 524 39 99

Polska

Servier Polska Sp. z o.o.
Tel: +48 (0) 22 594 90 00

Portugal

BIAL - Portela & C^a, S.A
Tel.: +351 22 986 61 00

România

Servier Pharma SRL
Tel: +40 21 528 52 80

Slovenija

Servier Pharma d.o.o.
Tel.: +386 (0)1 563 48 11

Slovenská republika

Servier Slovensko spol. s r.o.
Tel.:+421 (0)2 5920 41 11

Suomi/Finland

Servier Finland Oy

Tel: +39 (055) 623271

Puh/Tel: +358 (0)9 279 80 80

Κύπρος

Χ.Α.Παπαέλληνας & Σία Λτδ

Τηλ: +357 22741741

Sverige

Servier Sverige AB

Tel: +46 (8) 52 25 08 00

Latvija

SIA Servier Latvia

Tel. +371 67502039

United Kingdom

Servier Laboratories Ltd

Tel: +44 (0)1753 666409

This leaflet was last revised in

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site:

<http://www.ema.europa.eu>.

This leaflet is available in all EU/EEA languages on the European Medicines Agency website.